In this study, we demonstrate that high expression of LOC541471, GDAP1, SOD1, and STK25 may be biomarkers for risk stratification of AML patients, which may provide novel insight into evaluating prognosis, monitoring progression, and designing combinational targeted therapies. This evidence concerns the gene STK25 and acute myeloid leukemia.